Related Articles
Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non‑small cell lung cancer (Review)
Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement‑positive non‑small cell lung cancer: A case report
Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer
ALK inhibitors and advanced non-small cell lung cancer (Review)